Nav: Home

St. Jude unveils powerful resource to advance treatment of pediatric solid tumors

August 30, 2017

(MEMPHIS, Tenn. - Aug. 30, 2017) In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children's Research Hospital scientists have created the world's largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.

St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.

"Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent," said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. "This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors."

The project has already helped identify children with the muscle tumor rhabdomyosarcoma as the pediatric solid tumor patients most likely to benefit from combination chemotherapy that includes the experimental drug AZD1775. Planning has begun to incorporate the finding into an ongoing national clinical trial of the combination therapy for certain high-risk pediatric solid tumor patients.

Pediatric solid tumors are rare and so are the tissue samples and other resources needed to advance their understanding and treatment. Solid tumors of the bone, muscle, kidney, eye and other organs excluding the brain account for about 30 percent of childhood cancers. While the overall cure rate for these pediatric solid tumors is 75 percent, long-term survival is much lower for the approximately 30 percent of patients whose tumors return.

The Childhood Solid Tumor Network was created to share the patient tumor samples and other scientific resources Dyer and his colleagues have developed by learning to grow human tumors in the same organ in mice. The network now includes samples from more than 67 different patient tumors representing 12 types of pediatric solid tumors. Along with the tumor samples, information about the drug sensitivity, pharmacokinetics and the molecular make-up of the tumors is also available. Accessing the data requires no commitment to collaborate with St. Jude scientists.

The network has significantly expanded scientific resources for pediatric solid tumor research. For example, through the Childhood Solid Tumor Network, investigators studying the bone cancer osteosarcoma have an additional 20 patient tumor samples available for research to supplement five osteosarcoma cell lines now widely used to study the tumor. For the eye tumor retinoblastoma, available resources increased from two cell lines that have been widely used for research to an additional 18 retinoblastoma tumor samples.

"When the St. Jude-Washington University Pediatric Cancer Genome Project started to sequence the complete tumor and normal genome of pediatric cancer patients, we realized we needed better models to take full advantage of the discoveries," Dyer said. The genome project began in 2010 to sequence the genomes of 600 children and adolescents with some of the least understood and most difficult to treat cancers.

With the consent of patients and parents, researchers developed a system to grow St. Jude patient tumors in the same organ in mice. Such tumors are called orthotopic patient-derived xenografts. The standard approach has been to grow patient tumors in the flank of mice.

"The tumor samples were collected at diagnosis, recurrence and autopsy. Many came from patients with recurrent disease, which is important since previously we have had few models of recurrent pediatric solid tumors," Dyer said.

In the first five years, tumor samples from the biopsies and surgical specimens of 168 St. Jude patients resulted in 67 pediatric solid tumors, representing neuroblastoma, osteosarcoma, Wilms tumor, retinoblastoma, rhabdomyosarcoma and other less common tumors. Patient identification was removed.

A comprehensive analysis comparing the original patient tumor to the orthotopic xenografts showed many orthotopic patient-derived xenografts retained their "molecular fingerprint" even after being grown in successive generations of mice. That suggests the tumors maintain their molecular identity when grown in the same microenvironment in mice and provide more accurate models for tracking tumor development and drug sensitivity, Dyer said.

Along with whole-genome and whole-exome sequencing and gene-expression profiling, the analysis included the most detailed examination yet of the genomic or clonal complexity of pediatric solid tumor orthotopic xenografts. Solid tumors include subsets of cancer cells called clones that have different mutations. Understanding and addressing clonal diversity is key to obtaining better cure rates because failure to kill all the clones in a tumor leaves the door open for cells from one clone to multiply and trigger a fatal relapse.

Researchers also demonstrated the potential of orthotopic xenografts to speed drug discovery and advance multi-drug chemotherapy. The scientists developed a new method that uses orthotopic xenografts to enhance sensitivity of drug screening to help identify the most promising compounds to move into clinical trials. The results, which include more than 500,000 data points on drug sensitivity, metabolism and related information, are available to the global biomedical research community in what is believed to be the world's only free searchable database for childhood cancer.

Drug sensitivity screening helped researchers identify rhabdomyosarcoma as particularly sensitive to AZD1775, an inhibitor of the enzyme WEE1 that is involved in cell division and expressed at high levels in a variety of solid tumors. Investigators used orthotopic xenografts of high-risk rhabdomyosarcoma to show that the tumors responded when AZD1775 was combined with the chemotherapy drugs irinotecan and vincristine, which are currently used against rhabdomyosarcoma.

"This study shows that orthotopic patient-derived xenografts can serve as a bridge connecting basic and translational research to improve outcomes for patients," Dyer said. "It serves as the gold standard for development, characterization and use of patient-derived tumors."

Efforts continue to develop additional orthotopic patient-derived xenografts. The Childhood Solid Tumor Network now includes almost 100 pediatric solid tumors. Scientists plan to expand the effort to include induced pluripotent stem cells from children who are genetically predisposed to develop cancer. These are cells that have been reprogrammed to function as stem cells, which have the potential to become any cell type in the body.


The first authors are Elizabeth Stewart, M.D., and Sara Federico, M.D., both of the St. Jude Department of Oncology, and Xiang Chen, Ph.D., of the St. Jude Department of Computational Biology. The other authors are Anang Shelat, Cori Bradley, Brittney Gordon, Asa Karlstrom, Nathaniel Twarog, Michael Clay, Armita Bahrami, Burgess Freeman III, Beisi Xu, Xin Zhou, Jianrong Wu, Victoria Honnell, Monica Ocarz, Kaley Blankenship, Jason Dapper, James R. Downing, Jinghui Zhang, John Easton and Alberto Pappo, all of St. Jude; and Elaine Mardis and Richard Wilson of The Genome Institute, Washington University School of Medicine, St. Louis.

The research was funded in part by grants (CA21765, EY014867, EY018599, CA168875) from the National Institutes of Health, Alex's Lemonade Stand Foundation for Childhood Cancer, the Tully Family Foundation, the Peterson Foundation, St. Baldrick's Foundation, the National Pediatric Cancer Foundation, the Howard Hughes Medical Institute and ALSAC, the fundraising and awareness organization of St. Jude.

St. Jude Children's Research Hospital

Related Stem Cells Articles:

A protein that stem cells require could be a target in killing breast cancer cells
Researchers have identified a protein that must be present in order for mammary stem cells to perform their normal functions.
Approaching a decades-old goal: Making blood stem cells from patients' own cells
Researchers at Boston Children's Hospital have, for the first time, generated blood-forming stem cells in the lab using pluripotent stem cells, which can make virtually every cell type in the body.
New research finds novel method for generating airway cells from stem cells
Researchers have developed a new approach for growing and studying cells they hope one day will lead to curing lung diseases such as cystic fibrosis through 'personalized medicine.'
Mature heart muscle cells created in the laboratory from stem cells
Generating mature and viable heart muscle cells from human or other animal stem cells has proven difficult for biologists.
Mutations in bone cells can drive leukemia in neighboring stem cells
DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells.
Scientists take aging cardiac stem cells out of semiretirement to improve stem cell therapy
With age, the chromosomes of our cardiac stem cells compress as they move into a state of safe, semiretirement.
Purest yet liver-like cells generated from induced pluripotent stem cells
A team of researchers from the Medical University of South Carolina and elsewhere has found a better way to purify liver cells made from induced pluripotent stem cells.
Stem cell scientists discover genetic switch to increase supply of stem cells from cord blood
International stem cell scientists, co-led in Canada by Dr. John Dick and in the Netherlands by Dr.
Stem cells from diabetic patients coaxed to become insulin-secreting cells
Signaling a potential new approach to treating diabetes, researchers at Washington University School of Medicine in St.

Best Science Podcasts 2017

We have hand picked the best science podcasts for 2017. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: Radiolab

Oliver Sipple
One morning, Oliver Sipple went out for a walk. A couple hours later, to his own surprise, he saved the life of the President of the United States. But in the days that followed, Sipple's split-second act of heroism turned into a rationale for making his personal life into political opportunity. What happens next makes us wonder what a moment, or a movement, or a whole society can demand of one person. And how much is too much?  Through newly unearthed archival tape, we hear Sipple himself grapple with some of the most vexing topics of his day and ours - privacy, identity, the freedom of the press - not to mention the bonds of family and friendship.  Reported by Latif Nasser and Tracie Hunte. Produced by Matt Kielty, Annie McEwen, Latif Nasser and Tracie Hunte. Special thanks to Jerry Pritikin, Michael Yamashita, Stan Smith, Duffy Jennings; Ann Dolan, Megan Filly and Ginale Harris at the Superior Court of San Francisco; Leah Gracik, Karyn Hunt, Jesse Hamlin, The San Francisco Bay Area Television Archive, Mike Amico, Jennifer Vanasco and Joey Plaster. Support Radiolab today at
Now Playing: TED Radio Hour

Future Consequences
From data collection to gene editing to AI, what we once considered science fiction is now becoming reality. This hour, TED speakers explore the future consequences of our present actions. Guests include designer Anab Jain, futurist Juan Enriquez, biologist Paul Knoepfler, and neuroscientist and philosopher Sam Harris.